Hu, Chaoying http://orcid.org/0000-0002-0116-4387
Gao, Dan
Li, Dandan
Zhou, Dongli
Zhang, Lan http://orcid.org/0000-0002-5220-3171
Clinical trials referenced in this document:
Documents that mention this clinical trial
Chinese- and French-Manufactured Immediate-Release Glucophage® Bioequivalence: A Randomized, Open-Label, Crossover Study
https://doi.org/10.1007/s40268-022-00405-3
Article History
Accepted: 16 September 2022
First Online: 20 October 2022
Declarations
:
: This study was funded by Merck Serono Co., Ltd, China, an affiliate of Merck KGaA, Darmstadt, Germany.
: Dandan Li and Dongli Zhou are employees of Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd, China, an affiliate of Merck KGaA. Chaoying Hu, Dan Gao, and Lan Zhang report no conflicts of interest.
: The protocol and all documents were reviewed and approved by the Ethics Committee of Xuanwu Hospital Capital Medical University (No. [2017]030).
: All study participants provided written informed consent.
: All researchers, participants, institutions, and sponsors consented to the submission of this report to the journal.
: LZ was the principal investigator and contributed to all aspects of this work. CH and DG contributed to the study design and conduct. DL and DZ interpreted the data and drafted the manuscript. All authors approved the final version of the article for submission and agree to be accountable for all aspects of this work.
: The datasets used in the current analysis are available from Dandan Li upon reasonable request.